VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
UPC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
UPCUniverse Pharmaceuticals Inc.
$6.21$3M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

UPC logoUniverse Pharmaceuticals Inc.(UPC)Earnings, Financials & Key Ratios

UPC•NASDAQ
$5.44
Price updated Jul 2, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryTraditional Chinese medicine producers
AboutUniverse Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.Show more
  • Revenue$18M-22.4%
  • EBITDA-$2M+68.2%
  • Net Income-$4M+57.9%
  • EPS (Diluted)-1055.75+26.5%
  • Gross Margin35.28%+33.8%
  • EBITDA Margin-13.43%+59.0%
  • Operating Margin-16.33%+53.1%
  • Net Margin-20.56%+45.8%
  • ROE-7.23%+64.8%

UPC Price & Volume

Universe Pharmaceuticals Inc. (UPC) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Erosion Challenges Long-Term Viability

Investment Thesis • Updated 2025Q4

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Sustained Revenue Contraction

Key Thesis Takeaways

  • Universe Pharmaceuticals faces a structural decline in its core distribution business, evidenced by a 14.1% year-over-year revenue contraction in 2025Q4.
  • While the company maintains a healthy liquidity position with $33.6M in cash, the lack of operating leverage and negative margins suggest that the current business model is struggling to achieve sustainable profitability.
  • Investors should monitor the company's inability to convert revenue into positive cash flow, as the recent $7.8M operating cash outflow highlights significant operational inefficiencies.

Verdict Logic

the company's inability to generate positive operating cash flow, evidenced by a $7.6M outflow in 2025Q4, indicates that the current business model is not yet self-sustaining.

UPC Growth Metrics

Universe Pharmaceuticals Inc. (UPC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-10.27%
3 Years-23.66%
TTM-43.57%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM16.78%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM5.34%

Return on Capital

10 Years29.81%
5 Years-2.29%
3 Years-10.74%
Last Year-5.62%

Latest UPC News

Recent stock market news and headlines for Universe Pharmaceuticals Inc. (UPC)

GlobeNewsWire·Jun 26, 2026
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited (“Best Praise”), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company.

Globe News Wire·Jun 26, 2026
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited ("Best Praise"), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company.

Business Wire·Jun 16, 2026
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens' latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, F.

Peers Comparison

Key metrics vs top competitors for Universe Pharmaceuticals Inc. (UPC)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
UPC logoUPCUniverse Pharmaceuticals Inc.Current
$5.44$3.06M-0.01-22.44%-20.56%-7.23%—
HCWB logoHCWBHCW Biologics Inc.
$4.58$1.59M-0.07-97.89%-24.73%-102.39%—
XTLB logoXTLBXTL Biopharmaceuticals Ltd.
$2.49$273.96K-0.26—-227.72%-25.53%—
NUVB logoNUVBNuvation Bio Inc.
$5.42$1.88B-9.03698.96%-102.06%-44.1%—
CPRX logoCPRXCatalyst Pharmaceuticals, Inc.
$31.44$3.85B18.7119.78%37.08%23.65%—
TLPH logoTLPHTalphera, Inc.
$1.02$43.26M-3.00—-1425300%-92.98%—

Compare UPC vs Peers

Universe Pharmaceuticals Inc. (UPC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HCWB

Most directly comparable listed peer for UPC.

Scale Benchmark

vs MCK

Larger-name benchmark to compare UPC against a more recognizable public peer.

Peer Set

Compare Top 5

vs HCWB, XTLB, NUVB, CPRX

Get notified when UPC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

UPC Frequently Asked Questions

Universe Pharmaceuticals Inc. (UPC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Universe Pharmaceuticals Inc.'s revenue?

Universe Pharmaceuticals Inc. (UPC) reported $40.9M in revenue for fiscal year 2025. This represents a 43% increase from $28.5M in 2018.

How fast is Universe Pharmaceuticals Inc. growing?

Universe Pharmaceuticals Inc. (UPC) saw revenue decline by 22.4% over the past year.

Is UPC profitable?

Universe Pharmaceuticals Inc. (UPC) reported a net loss of $12.4M for fiscal year 2025.

Dividend & Returns
What is UPC's return on equity?

Universe Pharmaceuticals Inc. (UPC) has a return on equity (ROE) of -7.2%. Negative ROE indicates the company is unprofitable.

What is Universe Pharmaceuticals Inc.'s free cash flow?

Universe Pharmaceuticals Inc. (UPC) had negative free cash flow of $15.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in UPC back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →